<p>美国银行证券分析师杰森·泽曼斯基今天重申了对 Madrigal Pharmaceuticals 的持有评级，并设定了 550.00 美元的目标价。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>根据 TipRanks，泽曼斯基是一位五星级分析师，平均回报率为 21.3%，成功率为 57.59%。泽曼斯基覆盖医疗保健行业，专注于 Ligand Pharma、Insmed 和 Cytokinetics 等股票。</p>
<p>目前，分析师对 Madrigal Pharmaceuticals 的共识评级为强烈买入，平均目标价为 663.89 美元。</p>

Madrigal制药

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

医疗业 ETF - Vanguard

美国制药 ETF - iShares

标普生物技术 ETF - SPDR

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

标普全球医疗股指数 ETF - iShares

<p>美国银行证券分析师 Jason Zemansky 对 Madrigal Pharmaceuticals (MDGL) 维持了持有评级，目标价为 550 美元。这位分析师以 21.3% 的平均回报率和 57.59% 的成功率而闻名，覆盖医疗保健行业。市场对 Madrigal Pharmaceuticals 的共识为强烈买入，平均目标价为 663.89 美元</p>

<p>Bank of America Securities analyst Jason Zemansky reiterated a Hold rating on Madrigal Pharmaceuticals today and set a price target of $550.00.</p>
<div class="lb-trans"><p>美国银行证券分析师杰森·泽曼斯基今天重申了对 Madrigal Pharmaceuticals 的持有评级，并设定了 550.00 美元的目标价。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>According to TipRanks, Zemansky is a 5-star analyst with an average return of 21.3% and a 57.59% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Insmed, and Cytokinetics.</p>
<div class="lb-trans"><p>根据 TipRanks，泽曼斯基是一位五星级分析师，平均回报率为 21.3%，成功率为 57.59%。泽曼斯基覆盖医疗保健行业，专注于 Ligand Pharma、Insmed 和 Cytokinetics 等股票。</p>
</div><p>Currently, the analyst consensus on Madrigal Pharmaceuticals is a Strong Buy with an average price target of $663.89.</p>
<div class="lb-trans"><p>目前，分析师对 Madrigal Pharmaceuticals 的共识评级为强烈买入，平均目标价为 663.89 美元。</p>
</div>

Bank of America Securities Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)

Tip Ranks

美国银行

Ligand制药

Insmed

细胞动力

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

美国银行证券维持对 Madrigal 制药（MDGL）的持有评级